Biopharmas raising money in public or private financings, including: Akamis, Alpha Cognition, Biper, Candel, CG Oncology, Indapta, Reviva, Satellos, Xuanzhu.

Biopharmas raising money in public or private financings, including: Betaglue, Inventiva, Newamsterdam, Palatin, Promise, Trevi.

Biopharmas raising money in public or private financings, including: Aptevo, Candel, Esperion, Inovio, Next Innovative.

Biopharmas raising money in public or private financings, including: Briacell, Newamsterdam, Protara, Scilex.

Biopharmas raising money in public or private financings, including: Ambrosia, Angitia, Biovaxys, Cellectis, Chroma Medicine, Immunitybio, Merck, Nchroma, Nvelop, Okogen, Tasca, Veradermics.

CNS specialist Noema Pharma AG has added a further $44 million to its series B, bringing the total for the round to $147 million. The new financing bolsters the balance sheet as the Basel, Switzerland-based company progresses four phase II trials, with key data readouts expected in 2025.

Biopharmas raising money in public or private financings, including: Cardiff Oncology, Eikonizo, Maia, Novo Nordisk, Orthogon, Renaissthera, Sonnet.

Biopharmas raising money in public or private financings, including: Janux, Tharimmune, Universe.

Paradigm Biopharmaceuticals Ltd. raised AU$16 million (US$10.31 million) in a placement that will allow the company to start a global phase III trial with its lead product, Zilosul (injectable pentosan polysulfate/iPPS), to treat osteoarthritis.